

Rapid resistance detection is reliable for prompt adaptation of isoniazid resistant tuberculosis management

Olivier Bahuau^{1,2*}, Charlotte Genestet^{1,3*}, Elisabeth Hodille^{1,3}, Maxime Vallée³, Quentin Testard³, Caroline Tataï⁴, Julien Saison^{5,6}, Jean-Philippe Rasigade^{1,3}, Gérard Lina^{1,3,7}, Florence Ader^{1,2}, Oana Dumitrescu^{1,3,7} on behalf of the Lyon TB study group

* Co-first authors

1. CIRI - Centre International de Recherche en Infectiologie, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon-1, Inserm U1111, CNRS UMR5308, Lyon, France
2. Hospices Civils de Lyon, Service des Maladies infectieuses et tropicales, Lyon, France.
3. Hospices Civils de Lyon, Institut des Agents Infectieux, Laboratoire de bactériologie, Lyon, France
4. Centre de Lutte Anti Tuberculeuse, Bourg-en-Bresse, France
5. Infectious Diseases Department, Valence Hospital Center, Valence, France.
6. Clinical Research Unit, Valence Hospital Center, Valence, France.
7. Université Lyon 1, Facultés de Médecine et de Pharmacie de Lyon, Lyon, France

Corresponding author: oana.dumitrescu@chu-lyon.fr

Institut des Agents Infectieux

Hospices Civils de Lyon

103 Grande Rue de la Croix Rousse

F-69004 Lyon, France

Keywords: *Mycobacterium tuberculosis*, tuberculosis, isoniazid, drug-resistance, rapid detection

Running title: Rapid resistance detection improves HR-TB treatment

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract: (198 words)

Objectives: Appropriate tuberculosis (TB) management requires anti-TB drugs resistance detection. We assessed the performance of rapid resistance detection assays and their impact on treatment adaptation, focusing on isoniazid resistant (HR) TB.

Methods: From 2016 to 2022, all TB cases enrolled in 3 hospitals were reviewed for phenotypic drug susceptibility testing (p-DST) and genotypic DST (g-DST) performed by rapid molecular testing, and next generation sequencing (NGS). Clinical characteristics, treatment and outcome were collected for HR-TB patients. The concordance between g-DST and p-DST results, and delay between treatment initiation and results of g-DST and p-DST were respectively recorded to assess the contribution of DST results on HR-TB management.

Results: Among 654 TB cases enrolled, 29 were HR-TB. Concordance between g-DST by rapid molecular methods and p-DST was 76.9%, whilst concordance between NGS-based g-DST and p-DST was 98.7%. Rapid resistance detection significantly fastened HR-TB treatment adaptation (median delay between g-DST results and treatment modification was 6 days). It consisted in fluoroquinolone implementation for 17/23 patients; outcome was favourable except for 2 patients who died before DST reporting.

Conclusion: Rapid resistance detection fastened treatment adaptation. Also, NGS-based g-DST showed almost perfect concordance with p-DST, thus providing rapid and safe culture-free DST alternative.

Introduction (628 words)

Tuberculosis (TB), caused by *Mycobacterium tuberculosis* (Mtb), is the leading cause of death from a single infectious agent worldwide ¹. Effective TB control is threatened by the global emergence and spread of anti-TB drug resistant Mtb, which hampers antibiotics efficacy and therefore requires treatment adaptation to avoid treatment failure or relapse. Mtb drug resistance may present either as resistance to rifampicin (R) or isoniazid (H) alone, or as multi-drug resistant (MDR) TB (meaning that Mtb is resistant to both major first-line anti-TB drugs R and H) ¹.

The resistance to H, alone or combined with other drugs, is now the most common type of resistance to anti-TB drugs; the frequency of H-resistant R-susceptible TB (HR-TB) is greater than the one of R-resistant TB, and estimated at 7.4% of new and 11.4% of previously treated TB cases ². Evidence indicates increased rates of poor treatment outcomes, such as treatment failure, relapse, and progression to MDR-TB, when patients with HR-TB are treated with the standard anti-TB regimen ³.

To enable a prompt treatment adaptation, the World Health Organization (WHO) recommends an early detection of drug resistant TB through the use of a rapid diagnostic test ⁴. Accurate rapid detection of H resistance is challenging, as H resistance is linked to multiple genetic variations in different loci, resulting in technical difficulties, which explains the heterogeneous performance of rapid H resistance detection tests ⁵. Depending on the series and the genetic particularities of Mtb isolates tested, 30% to 70% of H resistant strains remain undetected ⁶.

Though time-consuming and requiring level 3 biological safety laboratories (BSL3), the standard reference for H susceptibility detection still relies on phenotypic culture-based drug susceptibility detection (p-DST). Testing using different critical concentrations offers the possibility to distinguish between low- and high- level of H resistance and may guide the decision for treatment regimen adaptations. *In vitro* data suggest that high-dose H may be

effective for the treatment of patients having low-level of HR-TB ⁷, while high-level of HR-TB requires the replacement of H by a fluoroquinolone (FQ), mainly levofloxacin (LFX) ³. As recommended by the WHO, it is essential that the resistance to R is excluded and, when possible, the resistance to FQ should also be excluded, prior to the implementation of LFX containing regimen, to help avert the acquisition of additional drug resistance ⁴.

Interestingly, recent progress has been done in the field of resistance detection based on next generation sequencing (NGS) to perform targeted or whole genome sequencing (WGS). The Deeplex Myc-TB® (GenoScreen, Lille, France) NGS-based tool provides a rapid identification of a large set of mutations in different resistance associated loci, up to 13 antibiotics, including all first-line anti-TB drugs and some second-line molecules such as FQ, linezolid, bedaquilin and injectable drugs, with performances equalizing those of p-DST ⁸. Likewise, WGS allows exhaustive drug resistance detection by using a mutation database validated by the WHO⁹. These NGS based diagnosis tests not only enable accurate detection of HR-TB, but may also provide information on pyrazinamide (Z), ethambutol (E) and FQ susceptibility, enabling a secure usage of LFX as recommended by the WHO guidelines ¹⁰.

France is a high-income country with low prevalence of TB cases (less than 10/100,000 inhabitants); in a previous retrospective study from 2016 and 2017, only 26% of patients diagnosed with TB had rapid molecular detection of H resistance, which correlated with early adaptation of HR-TB treatment ¹¹. Thus, the first objective of the present study was to explore the impact of rapid resistance detection tests, including NGS-based approach on the management of the patients and on the TB disease outcome, with a focus on HR-TB cases. The second objectives were to assess the performances of H resistance diagnosis tests and the compliance of HR-TB treatment regimens with international guidelines.

Methods (492 words)

Data collection

This is a retrospective study conducted in one tertiary-care (Hospices civils de Lyon, France, hosting 5362 hospitalisation beds) and two secondary-care hospitals (Bourg-en-Bresse and Valence, France, hosting respectively 860 and 800 hospitalisation beds). Were included, between November 2016 and July 2022, all patients diagnosed with TB and having a positive *Mtb* culture, at the central laboratory equipped with BSL3 and NGS facilities (Institut des Agents Infectieux, Lyon, France). For all *Mtb* clinical isolates, WGS analysis was performed in routine practice as part of the laboratory diagnosis. For patients with HR-TB, demographic data (age, sex, continent of birth), clinical presentation (symptoms, comorbidities, pulmonary, extra-pulmonary TB), anti-TB treatment, outcome and microbiological data (sputum smear results, time to positivity, p-DST and genotypic DST (g-DST), lineage) were collected. All the data were implemented in a database, in accordance with the decision 20-216 of the ethics committee of the Lyon University Hospital and the French legislation in place at the time of the study (Reference methodology MR-004). Relevant approval regarding access to patient-identifiable information are granted by the French data protection agency (*Commission Nationale de l'Informatique et des Libertés*, CNIL).

Mtb culture process

Mtb clinical isolates culture and p-DST were performed as previously described¹². G-DST by rapid molecular methods were performed on cultured *Mtb* on a routine basis as previously described, using the line probe assay GenoType MTBDRplus v2.0 test (Hain Lifescience, Nehren, Germany) from November 2016 to August 2020¹² and the MDR/MTB ELITE MGB® Kit (ELITechGroup SpA, Torino, Italy) on the ELITE InGenius® platform (ELITechGroup SpA)¹³ from September 2020 to July 2022. When clinically suspected, the R resistance was also performed using Xpert MTB/RIF Ultra (Cepheid, Sunnyvale, CA, USA) on the primary

sample as recommended ¹⁴. Finally, all R and H resistant isolates were retrospectively analysed using Deeplex Myc-TB® (GenoScreen, Lille, France) according to the manufacturer's instructions ¹⁵.

Whole-genome sequencing and bioinformatic analysis

Genomic DNA extraction, library preparation, short-read WGS using Illumina technology (San Diego, CA, USA) and bioinformatic analyses were performed as previously described ¹⁶. The reference genome coverage breadth was at least 92% with a mean depth of coverage of at least 30x. Variant calling with MuTect2 in microbial mode was performed. Variant calls were processed using the open access SNP-IT tool (<https://github.com/samlipworth/snplit>) to identify Mtb complex lineage based on WGS SNP calling ¹⁶. Mykrobe ¹⁷ command-line version is included in the pipeline to detect antibiotic resistance. Moreover, the WHO catalogue of mutations in Mtb complex and their association with drug resistance was also used as a database to annotate variants and to detect antibiotic resistance ⁹.

Statistical analysis

Data were expressed as count (percentage, %) for dichotomous variables and as median (interquartile range [IQR]) for continuous values. The number of missing values was excluded from the denominator. For dichotomous variables, χ^2 test was used and for continuous values, the paired t-test was used to compare groups. Statistical analyses were performed using GraphPad Prism® for Windows version 5.02 (GraphPad Software, La Jolla, CA, USA). A p-value < 0.05 was considered significant.

Results (1278 words)

Microbiological characterisation of Mtb isolates

Among the 654 patients with TB diagnosed at the Institut des Agents Infectieux of Lyon University Hospital from November 2016 to July 2022, 29 (4.4%) had HR-TB, 6 (0.9%) had R resistant TB and 9 (1.4%) had MDR-TB, according to p-DST (Figure S1A and C, Table S1). HR-TB was found in all lineages of *Mtb stricto sensu* (Figure S1B). The WGS revealed that the prevalence of FQ resistance was very low, only 3 cases were detected (0.46%); 1 strain was susceptible to first-line anti-TB drugs, 1 was an HR-TB strain, and 1 was an MDR-TB strain (Figure S1D and Table S1).

A total of 39 patients presented at least an H resistance, the most common mutations were the S315T on the *katG* gene, which is associated with high-level resistance, and the C-15T on the *inhA* promoter, which is associated with low-level resistance. Herein, rapid molecular methods failed to accurately identify 5 mutations associated with H resistance, concerning 9/39 (23%) TB patients with H resistance. Three mutations on the *katG* gene, that are associated with high-level resistance, were not detected, or gave an uninterpretable result. Moreover, 2 mutations on the *inhA* gene associated with the C-15T mutation on the *inhA* promoter were considered as low-level resistance mutations instead of high-level resistance (Table 1). Regarding NGS-based methods, the Deeplex Myc-TB method just failed to identify a single nucleotide deletion at the end of the coding region of the *katG* gene, at amino acid 975. WGS correctly identified all H-resistant isolates; overall the sensitivity of NGS-based methods for H resistance detection was 98.7%.

Regarding R resistance, among the 6 mutations detected, the most common was the S450L mutation on the *rpoB* gene. All mutations associated with R resistance were detected by g-DST, both by rapid molecular methods and by NGS-based methods. The use of these methods even allowed to identify a low-level R resistance mutation, the L452P mutation on the *rpoB* gene, which is not always detected by p-DST (Table 1).

Epidemiological and clinical characteristics of HR-TB patients

Among the 29 patients with HR-TB, the clinical data and information on treatment and outcome were available for 23 patients (Table S2); these data were missing for 6 patients who had been transferred to distant care centres upon TB management, and were therefore excluded from the analysis.

The median [IQR] age at diagnosis was 37 [21-53.5] years old, there were 16 (69.6%) male patients, and 19 (82.6%) were not born in France, coming from various countries within Africa, Asia, and Europe (Table 2). Five patients (21.7%) had comorbidities at TB diagnosis; 3 patients (13.0%) presented diabetes mellitus, and 2 of them (8.7%) also presented underlying chronic pulmonary conditions. Two patients (8.7%) had chronic viral hepatitis B and C, respectively, and a single patient (4.3%) was recently diagnosed with Human Immunodeficiency Virus (HIV) infection.

The patients presented asthenia (n=13; 56.5%), weight loss (n=13; 56.5%), fever (n=12; 52.1%), and night sweats (n=5; 21.7%). Pulmonary TB occurred in 18 patients (78.3%) while 5 patients (21.7%) had extrapulmonary TB. Among the patients with pulmonary TB, 9 patients (50%) showed an isolated pulmonary involvement, 4 patients (22.2%) had an associated lymph nodes involvement, 2 patients (11.1%) had an associated vertebral involvement, 2 patients (11.1%) had a central nervous system involvement, and 1 patient (5.5%) had a pleural involvement. Among the 5 patients with extrapulmonary TB, 2 patients (40%) exhibited osteoarticular TB, 2 patients (40%) had lymph nodes TB and 1 patient (20%) had pleural TB. Among the 23 patients with HR-TB, 10 (43.5%) had smear positive samples, and the median [IQR] time to positivity of the culture was 11 days [6-16]. According to p-DST, 8 (34.7 %) patients had low-level H resistance and 15 (65.3 %) had high-level H resistance. The median [IQR] delay between sampling and g-DST performed on cultured Mtb was 15.5 days [10-20]

and was significantly lower than the median [IQR] delay between sampling and p-DST of 36 days [30-50] ($p < 0.0001$).

Treatment and Outcome of HR-TB patients

Among the 23 patients with HR-TB, 16/23 (69.6%) received the standard regimen RHZE upon treatment initiation (Table 3, detailed in Table S2). An early detection of HR-TB on highly positive sputum in 2 (8.7%) patients resulted in the initiation of a FQ containing, H-free regimen from the start. Toxicity concerns were responsible for the start of non-conventional regimen for other patients. Following the molecular detection of H resistance in all patients, H doses were increased in 3 (13%) patients and H was switched to FQ in 10 (43.4%) patients. Additional phenotypic detection of H resistance resulted in 2 more switch from H to FQ. In total, 17 (73.9%) HR-TB patients received a FQ-containing regimen (13 received LFX, 3 received moxifloxacin (MOX) and 1 received both sequentially, Table S2). Toxicity or adverse events related to treatment modifications occurred in 5 (21.7%) patients, either due to hepatic cytolysis (n=2), epileptic seizure (n=1), tendinopathy (n=1), or neutropenia (n=1). During the continuation phase, 13 (56.5%) patients underwent treatment simplification combining two drugs, including R associated with either a FQ (n=8; 35%), Z (n=2; 8.7%), H (n=2; 8.7%) or E (n=1; 4.3%). The median (min-max) duration of these simplified regimens (from treatment modification to the end of anti-TB therapy) was 6 months (2-20). Overall, the median [IQR] treatment duration was 9 [6-12] months including 6 (26.1%) patients treated for 6 months, 8 (34.7%) patients treated for 9 months, and 7 (30.4%) treated > 9 months (range 10 to 22). In 8 patients, a longer therapy was explained by the extrapulmonary localisation and/or by risk factors of treatment failure (extensive cavitory disease and/or slow conversion of smear/culture). However, the 7 patients who were treated for > 9 months had no associated risk factors for relapse or treatment failure.

Among the 23 patients, the outcome was favourable in 21 (91.3%) patients, while 2 (8.7%) patients died from TB unrelated cause before treatment completion, after 2 days and 21 days respectively (Table S2).

Impact of microbiological results on HR-TB treatment

The anti-TB treatment was mostly initiated before the obtention of both p-DST and g-DST results; the median [IQR] delay between treatment initiation and p-DST was 32 days [28-45 days] and the median [IQR] delay between treatment initiation and g-DST was 10.5 days [4-12 days]. In 2 patients the g-DST was reported before treatment initiation, thus allowing an appropriate HR-TB management from the start (Figure 1A). Among the 23 patients with HR-TB, 19 (82.6%) were accurately detected using g-DST by rapid molecular methods. A total of 4 high-level H resistant cases were missed; 2 cases were presumed to have low-level H resistant, while 2 were presumed H susceptible (82.6% concordance between g-DST and p-DST).

The g-DST results generally led to the modification of anti-TB treatment, by replacing H by FQ or increasing the doses of H; the median [IQR] delay between g-DST results and treatment modification was 6 days [1-13 days]. In 2 patients, the treatment was only modified after p-DST results (Figure 1B); in 1 patient, the g-DST by rapid molecular method did not detect any H resistance associated mutation (*katG* deletion of amino acid 975, Table 1). In the other patient, for whom only the presumed low-level H resistance C-15T mutation on the *inhA* promoter was detected, the pursuit of the standard regimen combined with pharmacological monitoring was decided. In the other 2 patients, where H resistance mutations were not accurately detected by rapid molecular methods, 1 died before g-DST results (*katG* Q88P mutation), and 1, for whom g-DST only detected a mutation associated with low-level H resistance, LFX was implemented and then continued when p-DST revealed high-level H

resistance (supported by NGS-based DST showing a double mutation of *inhA* locus: *inhA* C1673425T -15 + *inhA* T1674481G I194T).

Discussion (1188 words)

The present study showed that rapid resistance detection tests allowed to accelerate the treatment adaptation in HR-TB patients. H resistance remains the most common type of resistance to anti-TB drugs. Global data on H resistance without concurrent R resistance were 7.4% in new TB cases and 11.4% in previously treated TB cases ², whilst this series included 29 TB patients with HR-TB representing 4.4% of TB managed cases. Until recently, HR-TB was thought to have similar treatment outcomes compared to drug-susceptible TB. However, many studies support that HR-TB is associated with higher rates of treatment failure and relapse than drug-susceptible TB ¹⁸. The increasing risk of MDR-TB in case of relapse, urged the elaboration of guidelines for appropriate management of HR-TB ³. To fasten the treatment adaptation, rapid testing for H resistance, in addition to R resistance, is largely encouraged by the WHO ⁴. The present results thus confirm previous reports showing that g-DST compared to p-DST significantly accelerates HR-TB diagnosis and appropriate anti-TB implementation, and should therefore be performed on routine basis by all TB diagnosis laboratories.

Though g-DST by rapid molecular methods may speed results by several weeks, the lack of sensitivity of H resistance remains a challenge ¹². This could be explained by the fact that clinical diagnosis companies mainly focus on R resistance detection as (i) MDR-TB always include resistance to R; (ii) the genetic support of R resistance is restricted to a short nucleotide sequence of *rpoB* locus; (iii) as a corollary there is an excellent feasibility of molecular tests ^{4,19}. Herein, the performances of rapid molecular R resistance detection were excellent. Conversely, regarding H resistance, the majority of rapid molecular methods only target codon

315 of *katG* locus (associated with high-level H resistance), leaving undetected other polymorphisms, frameshifts, and deletions on *katG*, though probably associated with phenotypic resistance⁵. This is linked to the genetic basis of H resistance; the heterogeneous performance of currently developed PCR-based assays for H-resistance detection can be explained by multi-locus spread genetic modifications^{6,13}. This issue seems to have been overpassed by the NGS-based assay Deeplex Myc-TB®, which herein displayed performances very similar to p-DST. Nevertheless, this assay needs every-day access to NGS services to be able to provide results in a time frame similar to rapid molecular tests.

Previously very useful to detect the different levels of H-resistance, p-DST was essential to determine HR-TB treatment regimens; using high-dose of H in patients having low-level H-resistance, or replacing H by LFX in patients having high-level H-resistance. In order to prevent inappropriate HR-TB management in case of misdiagnosis of H high-level resistance, the WHO pragmatically recommends the replacement of H by LFX within the anti-TB regimen, regardless of the H resistance level³. In the present series, 17/23 patients received FQ containing regimen in accordance with international guidelines. Since LFX containing regimen are increasingly implemented, it is more important to perform an accurate detection of H resistance than evaluating the level of H resistances. Although FQ resistance is still very low, 3/654 herein, to ensure safe implementation of FQ treatment, there is a need for a rapid detection of FQ resistance, in addition to a rapid and accurate resistance detection of the first-line anti-TB drugs. From this respect, to address the need of combined detection on multiple resistance markers, exhaustive NGS-based methods such as Deeplex® Myc-TB or WGS reveal to be more useful than prior developed real-time PCR-based methods. Herein, the excellent performances of NGS-based methods were confirmed for anti-TB drugs resistance detection, consistent with

the target product profile requested for Mtb DST ²⁰, and thus providing a culture-free DST solution for TB patients.

In this study, the median duration of anti-TB therapy was higher than the one recommended by the WHO 2018 guidelines: a duration of 6 months for LFX containing regimen ²¹. However, previous guidelines (2014) recommended a treatment duration of 6 to 9 months ²², thus, the prolongation to 9 months of treatment in absence of associated risk factors observed in our patients might be explained by the heterogeneous comprehension of successive guidelines. Unexpectedly, a regimen reduction to bitherapy was observed in 11 patients not managed with the RHZE standard regimen, including 8 patients with R+FQ regimen. This therapeutic option may be explained by the misinterpretation of the WHO guidelines, tending to mimic the switch to bitherapy performed upon the standard regimen, as well as by the intolerance or fear of intolerance in 6 months multi-antibiotic treatment. However, the favourable outcome observed for all the patients concerned by this simplification, may suggest that FQ containing regimens could be simplified upon the continuation phase.

Our study has limitations, firstly the enrolling centres were close geographically and linked to a single laboratory diagnosis, thus, it did not entirely reflect the French TB diagnosis and management landscape. Secondly, during the 5 years of the enrolling period, changes of the diagnosis methods were performed as well as changes of TB management guidelines, probably explaining the heterogeneity of treatments. However, our results were in line with a previous French multi-centre assessment covering the first part of our enrolling period ¹¹, revealing, in our case, a better implementation of g-DST and also a better compliance with the international HR-TB management guidelines, consistent with the 2018 WHO new recommendations.

The present study highlighted the importance of g-DST to safely engage HR-TB patients on adapted treatment. Also, NGS-based g-DST showed almost perfect concordance with p-DST, thus providing rapid and safe culture-free DST alternative. Moreover, this study revealed an important heterogeneity regarding patient management, probably due to the clinical complexity of patients, but also to misinterpretation of recent guidelines. We identified a need of simplified regimens to prevent toxicity and improve treatment adherence, in the context of TB management secured by accurate NGS-based resistance detection tools.

Declarations of interest: none

Acknowledgements: We thank Shanez Haouari (Direction de la Recherche en Santé, Hospices Civils de Lyon) for help in manuscript preparation.

References

- 1 World Health Organization, Geneva. Global tuberculosis report 2022. Available at <https://www.who.int/publications-detail-redirect/9789240061729>. Accessed December 13, 2022, 2022.
- 2 Dean Anna S., Zignol Matteo, Cabibbe Andrea Maurizio, Falzon Dennis, Glaziou Philippe, Cirillo Daniela Maria, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. *PLOS Med* 2020;**17**(1):e1003008. Doi: 10.1371/journal.pmed.1003008.
- 3 World Health Organization, Geneva. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Available at <https://apps.who.int/iris/rest/bitstreams/1211676/retrieve>. 2019.
- 4 World Health Organization, Geneva. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva, Switzerland; 2021.
- 5 Rivière E., Whitfield M. G., Nelen J., Heupink T. H., Van Rie A. Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimens. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2020;**26**(10):1332–7. Doi: 10.1016/j.cmi.2020.07.004.
- 6 Vogensen Vanessa B., Anthony Richard M., Kerstjens Huib A.M., Tiberi Simon, De Steenwinkel Jurriaan E.M., Akkerman Onno W. The case for expanding worldwide access to point of care molecular drug susceptibility testing for isoniazid. *Clin Microbiol Infect* 2022;**28**(8):1047–9. Doi: 10.1016/j.cmi.2022.03.033.
- 7 Dooley Kelly E., Miyahara Sachiko, von Groote-Bidlingmaier Florian, Sun Xin, Hafner Richard, Rosenkranz Susan L., et al. Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial. *Am J Respir Crit Care Med* 2020;**201**(11):1416–24. Doi: 10.1164/rccm.201910-1960OC.
- 8 Jouet Agathe, Gaudin Cyril, Badalato Nelly, Allix-Béguet Caroline, Duthoy Stéphanie, Ferré Alice, et al. Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs. *Eur Respir J* 2021;**57**(3):2002338. Doi: 10.1183/13993003.02338-2020.
- 9 Walker Timothy M., Miotto Paolo, Köser Claudio U., Fowler Philip W., Knaggs Jeff, Iqbal Zamin, et al. The 2021 WHO catalogue of *Mycobacterium tuberculosis* complex mutations associated with drug resistance: A genotypic analysis. *Lancet Microbe* 2022;**3**(4):e265–73. Doi: 10.1016/S2666-5247(21)00301-3.
- 10 World Health Organization Geneva. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in *Mycobacterium tuberculosis* complex: technical guide. 2018.
- 11 Bachir Marwa, Guglielmetti Lorenzo, Tunesi Simone, Billard-Pomares Typhaine, Chiesi Sheila, Jaffré Jérémy, et al. Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. *J Infect* 2022;**85**(1):24–30. Doi: 10.1016/j.jinf.2022.05.017.
- 12 Genestet Charlotte, Hodille Elisabeth, Berland Jean-Luc, Ginevra Christophe, Bryant Juliet E., Ader Florence, et al. Whole-genome sequencing in drug susceptibility testing of *Mycobacterium tuberculosis* in routine practice in Lyon, France. *Int J Antimicrob Agents* 2020;**55**(4):105912. Doi: 10.1016/j.ijantimicag.2020.105912.
- 13 Hodille Elisabeth, Genestet Charlotte, Delque Thomas, Ruffel Luna, Benito Yvonne, Fredenucci Isabelle, et al. The MTB/MDR ELITE MGB® Kit: Performance Assessment for Pulmonary, Extra-Pulmonary, and Resistant Tuberculosis Diagnosis, and Integration in the

- Laboratory Workflow of a French Center. *Pathog Basel Switz* 2021;**10**(2). Doi: 10.3390/pathogens10020176.
- 14 Hodille Elisabeth, Maisson Audey, Charlet Laurine, Bauduin Clyde, Genestet Charlotte, Fredenucci Isabelle, et al. Evaluation of Xpert MTB/RIF Ultra performance for pulmonary tuberculosis diagnosis on smear-negative respiratory samples in a French centre. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol* 2019;**38**(3):601–5. Doi: 10.1007/s10096-018-03463-1.
- 15 Feuerriegel Silke, Kohl Thomas A., Utpatel Christian, Andres Sönke, Maurer Florian P., Heyckendorf Jan, et al. Rapid genomic first- and second-line drug resistance prediction from clinical *Mycobacterium tuberculosis* specimens using Deeplex-MycTB. *Eur Respir J* 2021;**57**(1):2001796. Doi: 10.1183/13993003.01796-2020.
- 16 Genestet Charlotte, Hodille Elisabeth, Bernard Albin, Vallée Maxime, Lina Gérard, Le Meur Adrien, et al. Consistency of *Mycobacterium tuberculosis* Complex Spoligotyping between the Membrane-Based Method and In Silico Approach. *Microbiol Spectr* 2022;**10**(3):e0022322. Doi: 10.1128/spectrum.00223-22.
- 17 Bradley Phelim, Gordon N. Claire, Walker Timothy M., Dunn Laura, Heys Simon, Huang Bill, et al. Rapid antibiotic-resistance predictions from genome sequence data for *Staphylococcus aureus* and *Mycobacterium tuberculosis*. *Nat Commun* 2015;**6**(1):10063. Doi: 10.1038/ncomms10063.
- 18 Menzies Dick, Benedetti Andrea, Paydar Anita, Royce Sarah, Madhukar Pai, Burman William, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. *PLoS Med* 2009;**6**(9):e1000150. Doi: 10.1371/journal.pmed.1000150.
- 19 Jagielski Tomasz, Bakuła Zofia, Brzostek Anna, Minias Alina, Stachowiak Radosław, Kalita Joanna, et al. Characterization of Mutations Conferring Resistance to Rifampin in *Mycobacterium tuberculosis* Clinical Strains. *Antimicrob Agents Chemother* 2018;**62**(10):e01093-18. Doi: 10.1128/AAC.01093-18.
- 20 MacLean Emily Lai-Ho, Miotto Paolo, González Angulo Lice, Chiacchiarretta Matteo, Walker Timothy M., Casenghi Martina, et al. Updating the WHO target product profile for next-generation *Mycobacterium tuberculosis* drug susceptibility testing at peripheral centres. *PLOS Glob Public Health* 2023;**3**(3):e0001754. Doi: 10.1371/journal.pgph.0001754.
- 21 World Health Organization, Geneva. WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. 2018.
- 22 World Health Organization, Geneva. Companion handbook to the WHO guidelines for the programmatic management of drug resistant tuberculosis 2014.

Figures and Tables




Figure S1: Microbiological description of the TB patient cohort.

A. Resistance profile of TB patients diagnosed at the Lyon University Hospital. *6 patients were followed-up until the end of treatment in a different center. B. Distribution of Mtb lineages according to the resistance profile. C and D. Distribution of the 73 Mtb isolates resistant to at least one first-line drug by phenotypic drug susceptibility testing (p-DST, C) or genotypic DST (g-DST) performed by whole genome sequencing (WGS). Detection of resistance to fluoroquinolone was also performed by g-DST using WGS. R, rifampicin; H, isoniazid; Z, pyrazinamide; E, ethambutol; FQ, fluoroquinolone. Underlined: H high-level resistance; italics: *M. bovis* isolates.




Figure 1: Delay between anti-TB treatment and drug susceptibility testing results.

Genotypic DST by rapid molecular methods were performed on cultured Mtb, using the line probe assay GenoType MTBDRplus v2.0 test from November 2016 to August 2020 and the MDR/MTB ELITE MGB® Kit on the ELITE InGenius® platform from September 2020 to July 2022. Anti-TB treatment switch: replacement of H by FQ or increase in the dose of H.

Table 1: R and H resistance detection by phenotypic and genotypic methods.

Resistance mutations	No isolates	Phenotypic Rapid		NGS based methods	
		DST	molecular methods	Deeplex	WGS
Mutations associated with R resistance					
rpoB C761139A H445N	1	Resistant	Resistant	Resistant	Resistant
rpoB C761139T H445Y	2	Resistant	Resistant	Resistant	Resistant
rpoB C761155T S450L	10	Resistant	Resistant	Resistant	Resistant
rpoB CA761139TG H445C	1	Resistant	Resistant	Resistant	Resistant
rpoB CG761155TC S450F	1	Resistant	Resistant	Resistant	Resistant
rpoB T761161C L452P	1	Susceptible	Resistant	Resistant	Resistant
Mutations associated with H resistance					
katG DEL amino acids 1–492	1	<u>Resistant</u>	Undetermined	<u>Resistant</u>	<u>Resistant</u>
katG T2155849G Q88P	1	<u>Resistant</u>	Susceptible	<u>Resistant</u>	<u>Resistant</u>
katG DEL CG2155137C, amino acid 9751		<u>Resistant</u>	Susceptible	Susceptible	<u>Resistant</u>
katG C2155168G S315T	19	<u>Resistant</u>	<u>Resistant</u>	<u>Resistant</u>	<u>Resistant</u>
inhA C1673425T -15 + katG C2155168G1 S315T		<u>Resistant</u>	<u>Resistant</u>	<u>Resistant</u>	<u>Resistant</u>
fabG1 G1674048A L203L + katG2 C2155168G S315T		<u>Resistant</u>	<u>Resistant</u>	<u>Resistant</u>	<u>Resistant</u>
inhA C1673425T -15 + inhA T1674481G4 S94A		<u>Resistant</u>	Resistant	<u>Resistant</u>	<u>Resistant</u>
inhA C1673425T -15 + inhA T1674481G2 I194T		<u>Resistant</u>	Resistant	<u>Resistant</u>	<u>Resistant</u>

inhA C1673425T -15	7	Resistant	Resistant	Resistant	Resistant
inhA C1673423T -17	1	Resistant	Resistant	Resistant	Resistant

Genotypic DST by rapid molecular methods were performed on cultured Mtb, using the line probe assay GenoType MTBDRplus v2.0 test from November 2016 to August 2020 and the MDR/MTB ELITe MGB® Kit on the ELITe InGenius® platform from September 2020 to July 2022. For R resistant isolates, genotypic DST was also performed using Xpert MTB/RIF Ultra.

Bold: discordant results between p-DST and g-DST. Underlined: H high-level resistance.

Table 2: Main characteristics of the patients diagnosed with HR-TB

<i>Patients Characteristics</i>	
<i>Median age at diagnosis [IQR]</i>	37 [21-53.5]
<i>Male (%)</i>	16 (69.6%)
<i>French born / Not French born</i>	4/19
<i>Comorbidities</i>	
<i>Diabetes mellitus</i>	3 (13%)
<i>Underlying pulmonary condition</i>	2 (8.7%)
<i>Active chronic viral hepatitis (HBV or HCV)</i>	2 (8.7%)
<i>HIV infection</i>	1 (4.3%)
<i>Clinical presentation</i>	
<i>General symptoms</i>	
<i>Fever</i>	12 (52.1%)
<i>Night sweats</i>	5 (21.7%)
<i>Asthenia</i>	13 (56.5%)
<i>Loss of weight</i>	13 (56.5%)
<i>Pulmonary TB</i>	18 (78.2%)
<i>Pulmonary lesions exclusively</i>	9 (50%)
<i>Pulmonary lesions + lymph nodes involvement</i>	4 (22.2%)
<i>+ bone and joint involvement</i>	2 (11.1%)
<i>+ central nervous system involvement</i>	2 (11.1%)
<i>+ pleuritis</i>	1 (5.5%)
<i>Extrapulmonary TB</i>	5 (21.7%)
<i>Bone and joint</i>	2 (40%)
<i>Lymph nodes</i>	2 (40%)
<i>Pleural</i>	1 (20%)
<i>Microbiological characteristics</i>	
<i>Smear positive samples</i>	10 (43.5%)
<i>Time to positivity (days)</i>	11 [6-16]
<i>H resistance level</i>	
<i>Low-level resistance</i>	8 (34.7%)
<i>High-level resistance</i>	15 (65.3%)
<i>Delay between sampling and g-DST by rapid molecular methods (days)</i>	15.5 [10-20]
<i>Delay between sampling and p-DST (days)</i>	36 [30-50]

HBV: Hepatitis B Virus; HCV : Hepatitis C virus; HIV : Human Immunodeficiency Virus; p-

DST: phenotypic drug susceptibility testing; g-DST : genotypic drug susceptibility testing

Table 3. Main characteristics of the HR-TB patients' treatment regimens.

<i>Treatments characteristics</i>	
<i>Initial treatment</i>	
<i>Standard regimen (RHZE)</i>	<i>16 (69.6%)</i>
<i>FQ containing regimens</i>	<i>5 (21.7%)</i>
<i>Other regimens</i>	<i>2 (8.7%)</i>
<i>Treatment modification</i>	
<i>Switch H to FQ after H resistance detection</i>	<i>15 (65.2%)</i>
<i>H doses increased after H resistance detection</i>	<i>3 (13.0%)</i>
<i>Toxicity/Adverse events</i>	<i>5 (21.7%)</i>
<i>Standard drug susceptible TB regimen continuation phase</i>	<i>1 (4.3%)</i>
<i>No secondary modification</i>	<i>2 (8.7%)</i>
<i>Overall FQ containing regimens</i>	<i>17 (73.9%)</i>
<i>Regimens simplification (continuation phase with 2 molecules)</i>	
<i>- R + FQ</i>	<i>8 (34.7%)</i>
<i>- R + Z</i>	<i>2 (8.7%)</i>
<i>- R + H</i>	<i>2 (8.7%)</i>
<i>- R + E</i>	<i>1 (4.3%)</i>
<i>Duration of treatment</i>	
<i>Median in months [IQR]</i>	<i>9 [6-12]</i>
<i>6 months</i>	<i>6 (26.1%)</i>
<i>9 months</i>	<i>8 (34.7%)</i>
<i>> 9 months</i>	<i>7 (30.4%)</i>
<i>Death before completion of treatment</i>	<i>2 (8.7%)</i>

R: Rifampicin ; H: Isoniazid ; Z: Pyrazinamide ; E: Ethambutol; FQ: fluoroquinolone

<i>Patient (N*)</i>	<i>sex</i>	<i>Age range</i>	<i>Diagnosis period</i>	<i>Clinical presentation</i>	<i>Treatments</i>					<i>Treatment Duration (months)</i>	<i>Outcome</i>
1	F	60-69	Nov. 2016 - Aug. 2020	Cough and dyspnoea associated with fever, Meningitis. CT scan: Disseminated tuberculosis with Pulmonary lesions, mediastinal lymphadenopathies and vertebral lesions.	RHE + LVF					<1	Deceased (After 2 days from cardiogenic shock)
2	F	80-89	Nov. 2016 - Aug. 2020	Cough and thoracic pain with asthenia. History of pulmonary TB in the 1950s treated by pneumectomy. CT scan: thoracic abscess, puncture confirmed TB diagnosis.	RHZE	Switch RZE+LVF (Day 32)	Switch R+LVF (M2)	Switch R+Z (M5)		6	Favourable
3	M	80-89	Nov. 2016 - Aug. 2020	Dyspnoea and productive cough associated with fever and asthenia. Diabetes and Chronic Obstructive Pulmonary Disease CT scan: Disseminated tuberculosis with Pulmonary nodules, lymphadenopathies and vertebral lesions.	RHZE					<1	Deceased (After 21 days from severe dehydration)
4	F	60-69	Nov. 2016 - Aug. 2020	Chronic Hepatitis B and diabetes. CT scan: Pulmonary nodules	RHE+LVF		Switch RE+LVF (D27)			9	Favourable
5	M	10-19	Nov. 2016 - Aug. 2020	Productive cough and haemoptysis. Weight loss CT scan: Pulmonary nodules, cavitation and mediastinal lymphadenopathies	RHZE	Switch RHE+LVF (D40)	Switch RE+LVF (M2)	Switch LZD+LVF+CFZ (M3)	Switch R+LVF (M7)	20	Favourable
6	F	80-89	Nov. 2016 - Aug. 2020	Unproductive cough without general symptoms. Diabetes and anthracosis CT scan: isolated pulmonary nodules	RZE+LVF		Switch R+LVF (M2)			6	Favourable

7	M	10-19	Nov. 2016 - Aug. 2020	Productive cough and dyspnoea associated with fever, asthenia and weight loss. CT scan: isolated pulmonary nodules.	RHZE	Switch RHE (D2)	Switch RHhE (M3)	Switch RH (M6)	9	Favourable
8	M	50-59	Nov. 2016 - Aug. 2020	Productive cough and haemoptysis associated with fever, night sweats, asthenia and weight loss. CT scan: isolated Pulmonary nodules and cavitation.	RHZE	Switch RHZ (M2)	Switch RZ (M2,5)		6	Favourable
9	M	50-59	Nov. 2016 - Aug. 2020	Productive cough and chest pain associated with fever, night sweats, asthenia and weight loss. CT scan: pleural effusion without pulmonary lesions	RHZE	Switch RZE+L VF (D18)	Switch RZE (M2)	Switch RE (M3)	10	Favourable
10	M	30-39	Nov. 2016 - Aug. 2020	Cough and haemoptysis associated with fever and weight loss. CT scan: Pulmonary nodules and mediastinal lymphadenopathies.	RHZE	Switch RZE+LVF (D12)	Switch R+LVF M3		9	Favourable
11	M	20-29	Nov. 2016 - Aug. 2020	Productive cough and haemoptysis associated with fever, night sweats, asthenia and weight loss. CT scan: Pulmonary nodules, cavitation and lymphadenopathies	RHZE		Switch RH (M2)		9	Favourable
12	M	40-49	Nov. 2016 - Aug. 2020	Pulmonary TB in a patient with chronic hepatitis C.		RE+MOX			9	Favourable
13	M	0-09	Nov. 2016 - Aug. 2020	Cough and erythema nodosum associated with fever, asthenia and weight loss. CT scan: Pulmonary nodules and lymphadenopathies	RHZ		Switch RZE+LVF (D27)		6	Favourable

14	M	10-19	Nov. 2016 - Aug. 2020	Cough associated with fever, asthenia and weight loss. CT scan: Pulmonary lesions and lymphadenopathies	RHZE	Switch RHhZE (D10)	Switch RZE (M2)	9	Favourable		
15	M	30-39	Nov. 2016 - Aug. 2020	Cervical lymph nodes enlargement associated with asthenia and weight loss. CT scan: cervical lymphadenopathies and vertebral abscess.	RHZE	Switch RZE+LVF (D21)	Switch R+LVF (M2)	12	Favourable		
16	F	40-49	Nov. 2016 - Aug. 2020	Epileptic seizures without general symptoms. CT scan: Pulmonary nodules and disseminated lymphadenopathies	RHZE	Switch RZE+LVF (D29)	Switch RZE (M2)	14	Favourable		
17	M	20-29	Sept. 2020 - July 2022	Isolated Pulmonary TB	RHZE		Switch RZ+MOX (D14)	6	Favourable		
18	M	50-59	Sept. 2020 - July 2022	Productive cough and dyspnoea associated with fever, night sweats, asthenia and weight loss. CT scan: Pulmonary nodules, pleural effusion and mediastinal lymphadenopathies.	RHZE	Switch RHhZE + MOX (D22)	Switch RZE+MOX (M1)	Switch RZ+MOX (M4)	Switch R+MOX (M8)	10	Favourable
19	M	40-49	Sept. 2020 - July 2022	Lymphadenopathies associated with asthenia and weight loss in context of HIV infection discovery.	RZE					6	Favourable
20	F	0-09	Sept. 2020 - July 2022	Back pain associated with asthenia CT scan: vertebral osteomyelitis and abscess with spinal cord compression	RHZE	Switch RZE+LVF (D11)	Switch R+LVF (M2)	22	Favourable		
21	M	20-29	Sept. 2020 - July 2022	Isolated Pulmonary TB without general symptoms CT scan: Pulmonary nodules	RZE+LVF		Switch R+LVF (M3)	9	Favourable		
22	M	10-19	Sept. 2020 - July 2022	Productive cough and haemoptysis associated with fever, night sweats, asthenia and weight loss CT scan: Pulmonary nodules and cavitation	RHZE	Switch RZE+LVF (D1)	Switch RZ+LVF (M2)	Switch RZ (M4)	9	Favourable	

23	F	20-29	Sept. 2020 - July 2022	Productive cough associated with fever and weight loss CT scan: Pulmonary nodules and extensive cavitations.	RHZE	Switch RZE+LV F (D6)	Switch RZ+LVF +LZD (M4)	Switch R+MOX (M8)	14	Favourable
----	---	-------	------------------------	---	------	----------------------------	-------------------------------	----------------------	----	------------

Table S2 Patients detailed clinical presentation and therapeutic regimens

R: Rifampicin; H: Isoniazid; Z: Pyrazinamide; E: Ethambutol; LFX: levofloxacin; MOX: moxifloxacin

